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Abstract  
 Learning to associate cues or contexts with potential threats or rewards is adaptive and 
enhances survival. Both aversive and appetitive memories are therefore powerful drivers of 
behaviour but the inappropriate expression of conditioned responding to fear- and drug-related 
stimuli can lead to the development of anxiety-related and substance abuse disorders, respectively.  
These psychiatric diseases are associated with aberrant and persistent emotional memories and 
inadequate treatment using psychological therapies and/or medications, often leading to symptom 
relapse. Preclinical and clinical evidence indicates that cannabidiol, the main non-psychotomimetic 
phytocannabinoid found in Cannabis sativa, reduces anxiety in paradigms assessing innate 
responses to threat. Accumulating evidence from animal studies investigating the effects of 
cannabidiol on different fear memory processes also indicates that this drug reduces learned fear in 
paradigms that are translationally relevant to post-traumatic stress disorder and phobias. 
Cannabidiol does so by reducing fear expression acutely, and by disrupting fear memory 
reconsolidation and enhancing fear extinction, both of which can result in the lasting reduction of 
learned fear. Recent studies have also begun to determine the effects of cannabidiol on drug 
memory expression using paradigms with translational relevance to addiction. Emerging evidence 
suggests that cannabidiol reduces the expression of drug memories acutely and by disrupting their 
reconsolidation. Here we review the literature demonstrating the anxiolytic effects of cannabidiol 
before focusing on studies investigating its effects on various fear and drug memory processes. 
Understanding how cannabidiol regulates emotion and emotional memory processing may 
eventually lead to its use in treating anxiety-related and substance abuse disorders.  
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Introduction 
 Anxiety (e.g. generalized and social anxiety, panic, phobias), trauma-related (i.e. post-
traumatic stress disorder (PTSD)), and substance abuse disorders are serious forms of mental illness 
associated with a significant lifetime prevalence. These disorders pose an enormous social and 
financial burden as they are often chronic in nature and inadequately treated (Di Luca et al., 2011). 
Certain anxiety-related disorders (i.e. phobias, PTSD) and addiction are characterized by 
abnormally persistent emotional memories of fear- and drug-related stimuli. These discrete or 
contextual cues can trigger the emergence of symptoms or even their re-emergence after treatment, 
highlighting the limited effectiveness of currently available psychological and drug therapies to 
curtail symptom relapse over the long-term (Tronson and Taylor, 2013; Everitt, 2014; Kindt, 2014; 
Singewald et al., 2015). Thus there is an urgent need to improve the treatment of these disorders.  
 An area of real promise in this field concerns the use of existing or novel medications as 
adjuncts to psychological therapies to enhance the efficacy of treatment. Cannabidiol (CBD) is one 
such drug that shows therapeutic potential in a range of psychiatric diseases (Campos et al., 2012b). 
This phytocannabinoid is the main non-psychotomimetic constituent of the Cannabis sativa plant 
and mounting evidence indicates that CBD has anxiolytic properties (Blessing et al., 2015). Recent 
preclinical and clinical studies also indicate that CBD regulates different aversive and appetitive 
memory processes (Prud’homme et al., 2015; Jurkus et al., 2016). In this paper we begin with a 
brief historical account of the discovery of CBD and touch on the first studies that investigated its 
behavioural effects in rodents and humans. We then review the literature on CBD regulation of 
anxiety and the pharmacological and brain mechanisms involved. The bulk of the paper focuses on 
discussing the findings from the growing number of mostly preclinical studies that have examined 
the regulation of learned fear and, more recently, addictive drug memory processing by CBD. 
Importantly, these studies have used experimental procedures with clinical relevance for 
understanding the psychological and neurobiological mechanisms involved in the pathophysiology 
and treatment of anxiety, trauma-related, and substance abuse disorders. 
 
CBD discovery and initial studies on its behavioural effects 
The Cannabis sativa plant contains more than 100 chemically related terpenephenol 
components called phytocannabinoids (Izzo et al., 2009; Gold, 2015). Since the seminal work of 
Raphael Mechoulam’s group in the 1960s, Delta-9-tetrahydrocannabinol (THC) is considered the 
main component responsible for the pharmacological effects of the plant (Gaoni and Mechoulam, 
1964). The second major component of most samples of Cannabis sativa is CBD. Originally 
isolated by Adams and co-workers in 1940 (Adams et al., 1940), its structure was elucidated by 
Mechoulam and Shvo in 1963. Although the CBD molecule is similar to THC, it has a distinct 
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spatial conformation that could help to explain their different pharmacological properties. Whereas 
THC has a planar conformation, CBD presents a “bent” structure with two rings at a right angle to 
each other (Burstein, 2015). 
 Initial studies performed in the 1970s, mostly in Brazil, indicated that CBD could block 
some effects induced by THC in rodents (Karniol and Carlini, 1973; Russo and Guy, 2006). 
Following these initial studies, Zuardi and collaborators investigated if CBD could prevent the 
effects of high doses of THC in healthy human volunteers. They found that it attenuates the 
psychotomimetic and anxiogenic effects of THC (Zuardi et al., 1982). Although the mechanisms of 
action of these two drugs were completely unknown at that time, the fact that not all effects of THC 
were blocked by CBD indicated that the latter was not simply an antagonist of a putative THC 
receptor. On the contrary, the study suggested that CBD possesses its own antipsychotic and 
anxiolytic properties (Zuardi et al., 1982).  
 
Laboratory animal tests used to assess the anxiolytic properties of CBD 
The potential anxiolytic effect of CBD was initially investigated in preclinical studies. 
Several animal tests have been employed to explore the effects of putative anxiolytic drugs and the 
neurobiology of anxiety, which can be defined separately to fear as the emotional response to 
potential or anticipated (as opposed to actual and present) threat (Tovote et al., 2015). These tests 
are based on the measurement of defensive behaviours (either active or inhibitory) expressed in 
response to a threatening or unpleasant stimulus (Campos et al., 2013a). The initial preclinical 
studies investigating the possible anxiolytic-like effects of CBD were performed in learning-based 
models and produced mixed results. These apparently conflicting results were later explained by 
Guimaraes et al. (1990) using the elevated plus-maze (EPM). This is a commonly used test to 
investigate anxiety-like behaviour in preclinical studies and is based on the natural aversion rodents 
show to open spaces (Handley and Mithani, 1984; Pellow et al., 1985; Treit et al., 1993; Carobrez 
and Bertoglio, 2005).  
Using the EPM, and performing a full dose-response curve in rats, Guimaraes and co-
workers showed that acute systemic administration of CBD produces a typical ‘bell-shaped’ dose-
response curve, being anxiolytic at low and intermediate doses but not at high doses. Although 
some contradictory results exist in the literature, most studies using unlearned or operant 
conditioning models of anxiety have confirmed these initial findings and the studies investigating 
CBD effects in classical (Pavlovian) conditioning models also go in the same direction, which will 
be discussed separately below (summarized in Tables 1-2). Moreover, these anxiolytic effects of 
CBD in animals have been replicated in human studies using healthy subjects exposed to anxiety-
provoking stimuli or situations (Zuardi et al., 1982, 1993; Crippa et al., 2004; Fusar-Poli et al., 
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2009, 2010) and in patients with anxiety, and possibly also substance abuse, disorders 
(Bergamaschi et al., 2011, Crippa et al., 2011; Hurd et al., 2015; Shannon and Opila-Lehman, 2016; 
summarized in Table 3). 
 
Pharmacological mechanisms and brain sites involved in the anxiolytic effects of CBD 
The potential therapeutic effects of CBD have been related to multiple pharmacological 
mechanisms, including the agonism of serotonin 5-HT1A receptors, inhibition of re-uptake and/or 
metabolism of the endocannabinoid anandamide (resulting indirectly in cannabinoid receptor 
activation),  activation of transient receptor potential vanilloid 1 (TRPV1) channels, inhibition of 
adenosine re-uptake, antagonism of GPR55, agonism of PPARγ receptors, intracellular Ca
2+
 
increase, and anti-oxidative effects, among others. These pharmacological mechanisms have been 
recently discussed in several reviews (Izzo et al., 2009; Campos et al., 2012a; Ibeas Bih, 2015), to 
which the reader is referred. So far, however, only two of these mechanisms - 5-HT1A receptor 
activation and indirect potentiation of endocannabinoid transmission - have been implicated in the 
attenuation of defensive responses to threatening or stressful stimuli. 
Two primary brain systems organize defensive responses to threatening stimuli: one 
responsive to innate threats and the other responsible for the association between neutral and 
aversive stimuli, although the neural circuit mechanisms underlying the regulation of anxiety and 
learned fear show considerable overlap (for reviews see McNaughton and Corr, 2004; Canteras et 
al., 2010; Gross & Canteras, 2012; Tovote et al., 2015). The brain areas implicated in the anxiolytic 
effects of cannabidiol include certain medial prefrontal cortical subregions (e.g. prelimbic (PL) and 
infralimbic (IL) cortex), the bed nucleus of the stria terminalis (BNST), periaqueductal grey (PAG), 
and amygdala. This evidence comes from preclinical studies and functional imaging studies in 
humans, which have confirmed the involvement of some of these brain areas. For example, CBD 
reduced amygdala activation in both mice and humans (Todd and Arnold, 2016; Crippa et al., 
2004). Activity in and functional connectivity between the amygdala and anterior cingulate cortex, 
the homologous region to the rodent dorsomedial prefrontal cortex, were both also decreased by 
CBD when viewing fearful facial expressions (Fusar-Poli et al., 2009, 2010).  
 In an initial preclinical study using the EPM test, Campos and Guimarães (2008) showed 
that the anxiolytic-like effects of CBD injected into the dorsolateral PAG (dlPAG) were prevented 
by local treatment with the 5-HT1A receptor antagonist WAY100635. Even if this drug can also 
activate D4 receptors (Chemel et al., 2006), the anti-aversive effects of CBD were similar to other 5-
HT1A receptor agonists infused into the dlPAG (Graeff, 2002). 5-HT1A receptor involvement in the 
acute anxiolytic/anti-stress effect of CBD was further demonstrated in other relevant brain regions, 
including the BNST (Gomes et al., 2011) and IL cortex (Marinho et al., 2015). Moreover, systemic 
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treatment with 5-HT1A receptor antagonists was also able to prevent this CBD-induced anxiolysis 
(see Table 1).  
In the marble-burying test and after repeated administration, however, CBD effects on 
anxiety seem to depend on cannabinoid type 1 (CB1) receptors rather than 5-HT1A receptors 
(Casarotto et al., 2010; Campos et al., 2013; Nardo et al., 2014). Even if the (+)-CBD enantiomer 
shows affinity for CB1 receptors, the naturally occurring (-)-CBD does not bind to these receptors 
(Hanus et al., 2005), indicating that the CB1 receptor-mediated anti-aversive effects of CBD are 
probably indirect. Bisogno et al. (2001) showed that CBD blocked the reuptake and metabolism of 
anandamide in vitro. In the same direction, using embryonic hippocampal cells, Campos et al. 
(2013b) showed that the increase in cell proliferation induced by CBD is prevented by antagonism 
of either CB1 or CB2 receptors, as well as by overexpression of fatty acid amide hydrolase (FAAH), 
the enzyme responsible for anandamide metabolism.  More recently, Dale Deutsch’s group 
demonstrated that CBD binds to fatty acid binding proteins necessary for the transport of 
anandamide from the plasma membrane to intracellular FAAH, which might be a primary 
mechanism by which CBD decreases anandamide uptake/metabolism (Elmes et al., 2015). 
Consistent with these in vitro studies, the anti-stress (in mice) and antipsychotic (in humans) effects 
of repeated CBD administration were associated with increased hippocampal and serum levels, 
respectively, of anandamide (Campos et al., 2013b, Leweke et al., 2012). 
 
Emotional learning and memory processing 
We first summarize the psychological mechanisms involved in classical conditioning, a type 
of associative learning whereby discrete cues or contexts come to predict the occurrence of 
threatening or rewarding stimuli, before reviewing the evidence demonstrating a role for CBD in 
regulating different fear and drug memory processes. During conditioning an innocuous conditioned 
stimulus (CS), which can be a discrete cue (e.g. sound, light, odor) or a context (e.g. testing 
chamber/arena), becomes associated with an aversive (e.g. footshock) or appetitive (e.g. drug 
reward availability) unconditioned stimulus (US). After conditioning, the CS-US association 
undergoes consolidation into long-term memory and later presentation of or re-exposure to the CS 
alone initially elicits conditioned fear (e.g. freezing, avoidance) or drug-seeking (e.g. lever pressing, 
place preference) responses (Peters et al., 2009). Retrieval of the CS can make emotional memories 
labile by destabilizing the memory trace, which allows for these memories to be maintained or 
updated through the process of reconsolidation (Lee, 2009). Repeated presentations or prolonged 
exposure to the CS causes the extinction of emotional memories, resulting in the formation of a new 
CS-no US association which competes with the original emotional memory to suppress conditioned 
responding to the CS (Peters et al., 2009). Understanding how behavioural and/or pharmacological 
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interventions can attenuate conditioned responding, disrupt memory reconsolidation, and/or 
enhance extinction has clinical relevance given that all of these mechanisms are potential 
therapeutic strategies for alleviating the symptoms of PTSD (i.e. pathological fear) and addiction 
(i.e. drug craving) (Tronson and Taylor, 2013; Everitt, 2014; Kindt, 2014; Singewald et al., 2015). 
 
CBD effects on fear memory processing 
As alluded to above, growing evidence indicates that CBD also regulates learned fear (see 
Table 2). Systemic CBD administration has been shown to reduce the expression of fear memory 
when given acutely (Zuardi and Karniol, 1983; Resstel et al., 2006; Lemos et al., 2010; Jurkus et al., 
2016). CBD has also been reported to impair the acquisition of fear learning, given that acute 
systemic administration before fear conditioning resulted in attenuated fear expression during later 
memory retrieval testing (Levin et al., 2012). Fear memory consolidation is equally impaired by 
acute systemic administration of CBD when given after conditioning (Stern et al., 2016). In 
contrast, the reported effects of repeated CBD administration on fear memory expression are still 
scarce and conflicting. In one study, daily injections for 14 days prior to conditioning enhanced fear 
expression during retrieval testing, suggesting that chronic CBD facilitated fear learning (ElBatsh et 
al., 2012), whereas another study showed no effect of CBD on fear conditioning when administered 
for 21 days (Cheng et al., 2014).  
Studies indicate that CBD also modulates the extinction and reconsolidation of conditioned 
fear, leading to lasting effects on learned fear expression. Intracerebroventricular infusions of CBD 
given before three extinction sessions resulted in enhanced contextual fear extinction (Bitencourt et 
al., 2008). Systemic administration of CBD given acutely before extinction has been shown to 
affect contextual fear extinction depending on the strength of fear conditioning beforehand. CBD 
impaired extinction after weak conditioning but enhanced extinction after strong conditioning (Song 
et al., 2016). However, CBD given systemically before auditory fear extinction reduced fear 
expression acutely without affecting extinction memory (Jurkus et al., 2016). Interestingly, a study 
in humans also showed that CBD had no effect on the extinction of visual fear memory when given 
before extinction but it did enhance extinction memory when given immediately after extinction 
(Das et al., 2013).  
Contrary to the reported facilitatory effects of CBD on fear extinction, this drug has been 
shown to disrupt the reconsolidation of contextual fear memory after its brief retrieval (Stern et al., 
2012; Gazarini et al., 2014; Stern et al., 2015), although these contrasting effects of CBD on fear 
extinction and memory reconsolidation both result in the lasting reduction of learned fear 
expression. The disruptive effect of systemic CBD administration on reconsolidation required that it 
was given immediately after memory retrieval as CBD had no effect if it was given without, or six 
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hours after, retrieval. CBD was also able to disrupt the reconsolidation of both newer and older fear 
memories. Moreover, the subsequent reduction of learned fear expression lasted for over 21 days 
and was not reinstated by later shock presentation, indicating that the effects of CBD were due to 
disrupted memory reconsolidation and not enhanced extinction (Stern et al., 2012).  
In another study, CBD given immediately after retrieval disrupted the reconsolidation of an 
abnormally persistent fear memory when the partial NMDA receptor agonist D-cycloserine was 
first administered before retrieval to facilitate memory destabilization. Fear memory was 
strengthened pharmacologically by enhancing adrenergic transmission immediately after 
conditioning, resulting in generalized fear expression and impaired fear suppression by extinction 
(Gazarini et al., 2014). Understanding the mechanisms underlying reconsolidation disruption of 
such fear memories is important because evidence indicates that strong fear memories can show 
resistance to pharmacological disruption of reconsolidation (Lee, 2009), which has implications for 
using this potential therapeutic approach to weaken traumatic memories in the treatment of PTSD.  
 
Pharmacological mechanisms and brain sites involved in the effects of CBD on learned fear 
 Just as the anxiolytic effects of CBD involve a direct effect on 5-HT1A receptors and an 
indirect effect on cannabinoid receptors via elevated endocannabinoid levels, so too do its effects on 
different fear memory processes. Similarly, there is overlap in the neural circuitry involved in 
mediating the effects of CBD on anxiety and learned fear. The reduction in conditioned fear 
expression induced by CBD was accompanied by attenuated c-Fos expression in the PL and IL 
cortices and the BSNT. Moreover, CBD infusion into the BNST or PL cortex reduced fear memory 
expression, although infusing CBD into the IL cortex enhanced the expression of learned fear 
(Lemos et al., 2010). This discrepancy between the effects of CBD infused into the PL or IL cortex 
is likely due to these medial prefrontal cortical subregions exerting opposing influences on learned 
fear, with the former facilitating its expression and the latter being involved in its suppression 
and/or extinction (Fenton et al., 2014; Giustino and Maren, 2015). The regulation of conditioned 
fear expression by CBD in these brain areas was shown to be 5-HT1A receptor-dependent (Gomes et 
al., 2012; Fogaça et al., 2014; Marinho et al., 2015). The inhibitory effect of CBD on the acquisition 
of fear conditioning has also been shown to depend on 5-HT1A receptor activation in the nucleus 
accumbens shell (Norris et al., 2016).  
In contrast to the acquisition and expression of fear memory, the consolidation, 
reconsolidation, and extinction of learned fear involves (indirect) cannabinoid receptor activation. 
The inhibitory effect of CBD on fear memory consolidation was blocked by CB1 or CB2 receptor 
antagonist pretreatment (Stern et al., 2016). The facilitatory effect of intracerebroventricular CBD 
infusion on fear extinction were inhibited by prior CB1 receptor antagonism but not TRPV1 channel 
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blockade (Bitencourt et al., 2008). CBD was shown to act in the IL cortex to facilitate fear 
extinction as infusing CBD into this region enhanced extinction, an effect which also depended on 
CB1 receptors (Do Monte et al., 2013). The disruptive effect of CBD on fear memory 
reconsolidation was blocked by pretreatment with a CB1 receptor antagonist given systemically or 
infused into the PL cortex, whereas prior 5-HT1A receptor antagonism had no effect on the 
disruption of reconsolidation by CBD (Stern et al., 2012, 2014).   
 
CBD effects on addictive drug memory processing 
In contrast to the study of fear memories, to date there has been a much more limited 
exploration of the effects of CBD on addictive drug-related memories. This necessitates a narrative 
review of the relevant literature, which follows below. Moreover, the small number of studies has 
been conducted across a variety of experimental paradigms, with different drugs of abuse. These 
drugs can elicit sensitized responses with intermittent repeated administration, which is context-
dependent and thereby reliant upon context-drug associations. Similarly, the acquisition and 
expression of conditioned place preference behaviour depends upon the integrity of context-drug 
and/or cue-drug associations. Finally, cue-drug associations can precipitate cue-induced relapse of 
drug seeking in rodents previously trained to self-administer drug (Aguilar et al., 2009; Steketee and 
Kalivas, 2011). Each of these paradigms can be studied using stimulants (e.g. cocaine, 
amphetamine), opiates (e.g. heroin, morphine) and other drugs (e.g. alcohol, nicotine, etc.). 
Unlike THC, studies have shown that CBD lacks any rewarding effects of its own given that 
it fails to induce conditioned place preference or enhance the reinforcing effects of electrical brain 
self-stimulation (Parker et al., 2004; Vann et al., 2008; Katisdoni et al., 2013). In a study of 
amphetamine-induced locomotor sensitization, infusions of CBD (100 ng) into the shell subregion 
of the nucleus accumbens attenuated the development of locomotor sensitization (Renard et al., 
2016). While this might suggest that CBD impaired the formation of an amphetamine memory that 
supports locomotor sensitization, these findings were within the context of mesolimbic mechanisms 
involved in the potential antipsychotic action of CBD. Moreover, even though the attenuation of 
locomotor sensitization was paralleled by modulation of cellular mechanisms of synaptic plasticity, 
it remains a challenge to disambiguate learning-related behavioural effects from modulation of drug 
reward (c.f. Katsidoni et al., 2013; Prud'homme et al., 2015), which would impact upon reward-
dependent learning. The non-mnemonic interpretation is supported by a failure of CBD to prevent 
the acquisition of amphetamine place preference (Parker et al., 2004). However, while it appears 
that CBD does not disrupt the formation of amphetamine-related memories, this does not rule out 
potential effects on memories formed in relation to other drugs of abuse. 
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 Subsequent to their acquisition, CBD might affect the expression of drug memories. Here, 
there appears to be a contrast depending upon the drug reward under study. Acute administration of 
CBD (5 and 10 mg kg
-1
) did not alter cocaine self-administration or cue-induced relapse to cocaine 
seeking (Mahmud et al., 2016), and so failed to replicate an earlier study of heroin self-
administration (Ren et al., 2009). While CBD (5 and 20 mg kg
-1
) similarly did not alter heroin self-
administration, there were effects on cue-induced relapse to heroin seeking (Ren et al., 2009), a 
measure of cue-heroin memory expression. CBD (5 mg kg
-1
) reduced responding at a cue-induced 
relapse test, but only when given 24 hr, and not 30 min, prior to the test. This long-lasting impact 
upon the expression of the cue-heroin memory was even more persistent (up to 14 days) when three 
consecutive daily injections of 5 mg kg
-1
 CBD were given. This ability of CBD to have such long-
lasting effects may be mediated by an upregulation of AMPA GluR1 receptors in the nucleus 
accumbens (Ren et al., 2009).  
 The impaired expression of cue-heroin relapse in response to CBD administration in animals 
suggests that this drug might have anti-relapse properties in opiate addiction in humans. This has 
been explored in a preliminary study of heroin addicts, in which participants were given daily doses 
of CBD (400 or 800 mg) or placebo for 3 days (Hurd et al., 2015). CBD reduced craving both 24 hr 
and 7 days later, mirroring the preclinical rodent study (Ren et al., 2009). This beneficial effect of 
CBD may not be limited to opiate addiction as a conceptually similar, albeit more modest, effect 
was also previously observed in tobacco smokers (Morgan et al., 2013). In this small week-long 
study, smokers were instructed to inhale a metered dose of CBD (400 µg) or placebo when they felt 
like smoking. CBD acutely reduced the number of cigarettes smoked but this effect was not 
maintained after the cessation of CBD administration. Interestingly, and in contrast to the heroin 
study, CBD did not alter craving, either acutely or persistently. Therefore, it is not clear whether 
CBD has generalised effects on the expression of cue-drug memory to elicit craving and precipitate 
relapse, or whether its effects are specific to certain classes of addictive drugs. 
 For the maintenance (i.e. reconsolidation) of drug-related memories, there is a single study 
on morphine and cocaine conditioned place preference. When the place preference memory was 
briefly reactivated in order to trigger reconsolidation, CBD administration (10 mg kg
-1
) immediately 
thereafter led to an impairment in the subsequent maintenance of both cocaine and morphine 
memories to reduce place preference at test (de Carvalho and Takahashi, 2016). This was a long-
lasting effect, which is usually evidence for reconsolidation impairments. However, the study 
lacked a true non-reactivation control, and so the long-lasting impairment, especially for morphine 
place preference, is not dissimilar to the aforementioned persistent reduction in the expression of 
cue-heroin memories in the self-administration setting (Ren et al., 2009). Therefore, it remains 
unclear whether CBD indeed impairs the reconsolidation of drug memories. Nevertheless, there are 
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indications from the comparison between the place preference and self-administration studies to 
suggest that their results might be underpinned by qualitatively different processes. For example, 
while the CBD-induced impairment failed to ameliorate heroin-primed reinstatement of drug 
seeking (Ren et al., 2009), post-reactivation CBD did prevent morphine-primed reinstatement of 
place preference (de Carvalho and Takahashi, 2016). Moreover, the contrasting effects of post-
reactivation CBD and acute CBD treatment on the subsequent expression of cocaine memories (de 
Carvalho and Takahashi, 2016) suggests that the impairment in cocaine place preference is not 
simply explained by long-lasting modulation of drug memory expression. 
 Similarly, there is a single study of CBD and drug memory extinction. Injection of CBD (5 
mg kg
-1
) prior to an extinction trial enhanced the subsequent reduction in cocaine and amphetamine 
place preference (Parker et al., 2004). Despite the lack of a no-extinction control, the observation 
that CBD reduces the expression of stimulant-induced place preference again suggests that such a 
reduction was, at least in part, due to the concomitant extinction trial. Interestingly, the effect of 
CBD to reduce cocaine and amphetamine place preference in this extinction study (Parker et al., 
2004) is rather similar to the previous observation that CBD impairs the reconsolidation of 
morphine and cocaine memories in the same place preference setting (de Carvalho and Takahashi, 
2016). Indeed, while there was a difference in the timing of CBD administration between the two 
studies, the single behavioural trial that served to extinguish (Parker et al., 2004) or destabilise (de 
Carvalho and Takahashi, 2016) the drug memory did not differ greatly. The extinction trial was 15 
min in duration, compared to a 10 min reactivation trial, although the former was a confinement to 
the drug-paired chamber, whereas the latter was a test. Moreover, the conditioning parameters were 
rather similar across the two studies, and also in prior studies of reconsolidation that have used 30-
min confined reactivation trials for amphetamine place preference (Sakurai et al., 2007), 20-min 
confined reactivation trials for cocaine place preference (Valjent et al., 2006) and 10-min confined 
reactivation trials for morphine and nicotine place preference (Wang et al., 2008; Fang et al., 2011). 
Given also that the parameters of appetitive memory reconsolidation and extinction are usually well 
distinguished, such that they are each typically defined by much different durations of context re-
exposure or numbers of cue presentations (Flavell and Lee, 2013), it is unclear if CBD both 
enhances extinction and impairs reconsolidation of drug memories. It is perhaps more likely that the 
two observed effects of CBD to reduce later drug place preference (Parker et al., 2004; de Carvalho 
and Takahashi, 2016) instead reflect qualitatively similar processes. Appealing simply to the 
parametric comparisons presented above, we would conclude that there is stronger evidence for 
CBD impairing drug memory reconsolidation than there is for it enhancing drug memory extinction. 
Furthermore, given that pharmacological enhancement of extinction is usually dependent upon 
appreciable extinction-mediated memory reduction (Webber et al., 2007; Bouton et al., 2008), and 
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there was no evidence for any such reduction in the CBD study (Parker et al., 2004), it remains 
unclear if CBD actually enhances drug memory extinction. 
 
Concluding remarks and future directions 
Converging lines of evidence have established that acute CBD treatment is anxiolytic in 
both animals and humans. A growing number of preclinical studies also indicate that this drug 
reduces fear memory expression when given acutely. Importantly, CBD results in an enduring 
reduction in learned fear expression when given in conjunction with fear memory reconsolidation or 
extinction by disrupting the former and facilitating the latter. This makes CBD a potential candidate 
for testing as a pharmacological adjunct to psychological therapies or behavioural interventions 
used in treating PTSD and phobias. These effects of CBD are mediated at least in part by 5-HT1A 
receptors and indirectly via endocannabinoid-mediated action on cannabinoid receptors, although 
the involvement of other possible pharmacological mechanisms has not yet been investigated. 
Studies have begun to elucidate the neural circuit mechanisms underlying the effects of CBD on 
anxiety and learned fear. The recent functional imaging studies in humans that have examined the 
alterations in brain activity that accompany the anxiolytic effects of CBD may inform future 
preclinical and clinical studies investigating the wider neural circuitry involved in mediating its 
effects on fear memory processing. In contrast to anxiety and learned fear, research on CBD 
regulation of addictive drug memory processing is still in its infancy. Further studies are therefore 
needed to determine the psychological, pharmacological and brain mechanisms involved in the 
attenuation of drug memory expression related to different classes of abused drugs. Such research 
may lead to the potential use of CBD for treating anxiety-related and substance abuse disorders in 
the future. Furthermore, given their significant co-morbidity (Tipps et al., 2014), using CBD could 
also be investigated as a common treatment for these disorders.  
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Table Legends 
Table 1. CBD effects on anxiety-like behaviour in male animals. 5-HT1A: serotonin1A; BNST: bed 
nucleus of the stria terminalis; BZD: benzodiazepine; CB1: cannabinoid type 1; CUS: chronic 
unpredictable stress, dlPAG: dorsolateral periaqueductal gray; EPM: elevated plus-maze, ETM: 
elevated T-maze; ICR: Institute of Cancer Research; i.c.v.: intracerebroventricular; IL: infralimbic, 
i.p.: intraperitoneal; LDT: light-dark test, MBT: marble burying test, NSF: novelty suppressed 
feeding, PL: prelimbic; SHR: spontaneous hypertensive rats; THC: delta-9-tetrahydrocannabinol; 
TRPV1: transient receptor potential vanilloid 1. 
Table 2. CBD effects on learned fear processing in male animals. 5-HT1A: serotonin1A; AFC: 
auditory fear conditioning; BNST: bed nucleus of the stria terminalis; BZD: benzodiazepine; CB1: 
cannabinoid type 1; CB2: cannabinoid type 2; CFC: contextual fear conditioning; i.c.v.: 
intracerebroventricular; IL: infralimbic; i.p.: intraperitoneal; OFC: olfactory fear conditioning; PL: 
prelimbic; THC: delta-9-tetrahydrocannabinol. 
Table 3. CBD effects on anxiety in humans. 5-HT1A: serotonin1A; fMRI: functional magnetic 
resonance imaging; PTSD: post-traumatic stress disorder; SCR: skin conductance response; 
SPECT: single-photon emission computed tomography; THC: delta-9-tetrahydrocannabinol. 
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Table 1.  
Reference Test used Strain, species, effective dose, and 
route/site of administration 
Effect Pharmacological 
mechanism 
Guimarães et 
al., 1990 
EPM Wistar rats, 2.5-10 mg kg
-1
, i.p. Anxiolytic (bell-shaped dose-
response curve) 
Not tested 
Onaivi et al., 
1990 
EPM ICR mice, 1 and 10 mg kg
-1
, i.p.  Anxiolytic (bell-shaped dose-
response curve) 
BZD (blocked by flumazenil)  
Guimarães et 
al., 1994 
EPM Wistar rats, 5 mg kg
-1
, i.p. Anxiolytic Not tested 
Bitencourt et 
al., 2008 
Fear-potentiated EPM Wistar rats, 6.4 nmol, i.c.v. Anxiolytic Not tested 
Campos and 
Guimarães, 
2008 
EPM Wistar rats, 30 nmol, intra-dlPAG Anxiolytic (bell-shaped dose-
response curve) 
5-HT1A receptor activation 
Campos and 
Guimarães, 
2009 
EPM Wistar rats, 30 nmol, intra-dlPAG 
(60 nmol effective when combined 
with a TRPV1 channel antagonist) 
Anxiolytic Lack of anxiolytic effect of 
high doses associated with 
TRPV1 channel activation 
Malone et al., 
2009 
THC-induced decrease in 
social interaction 
Sprague Dawley rats, 20 mg kg
-1
, 
i.p. 
Anxiolytic Not tested 
Resstel et al., 
2009 
Restraint stress, autonomic 
changes, delayed (24 h) 
anxiogenic effect in EPM 
Wistar rats, 10 mg kg
-1
, i.p. Anti-stress 5-HT1A receptor activation 
Casarotto et 
al., 2010 
MBT C57BL/6 mice, 15-60 mg kg
-1
, i.p. Anti-compulsive Indirect CB1 receptor 
activation 
Soares et al., 
2010 
ETM, electrical 
stimulation of dlPAG 
Wistar rats, 15-60 nmol, intra- 
dlPAG 
Anxiolytic/panicolytic 5-HT1A receptor activation 
Long et al., 
2010 
Open field and light-dark 
tests 
C57BL/6 mice, 1 mg kg
-1
 (light-
dark test) and 50 mg kg
-1
 (open-
field), i.p., daily for 21 days 
Anxiolytic Not tested 
Gomes et al., 
2011 
EPM Wistar rats, 30 nmol, intra-BNST Anxiolytic 5-HT1A receptor activation 
Granjeiro et 
al., 2011 
Restraint stress, autonomic 
reactivity, delayed (24 h) 
Wistar rats, 30 nmol, intra-cisterna 
magna 
Anti-stress Not tested 
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anxiogenic effect in EPM 
Campos et al., 
2012 
EPM after predator (cat) 
exposure 
Wistar rats, 5 mg kg
-1
, i.p., daily for 
7 days 
Anxiolytic 5-HT1A receptor activation 
Deiana et al., 
2012 
MBT Swiss mice, 120 mg kg
-1
, orally or 
i.p. 
Anticompulsive Not tested 
Long et al., 
2012 
Open field and light-dark 
tests 
C57BL/6 Arc mice, 1 and 100 mg 
kg
-1
, i.p. daily for 13 days 
Anxiolytic  
(open-field only) 
Not tested 
Uribe-Mariño 
et al., 2012 
Snake exposure Swiss mice, 0.3-30 mg kg
-1
, i.p. Panicolytic Not tested 
Hsiao et al., 
2012 
Repeated EPM and open-
field  
Wistar rats, 3.2 nmol, intra-central 
amygdaloid nucleus 
Anxiolytic Not tested 
Campos et al., 
2013 
EPM and NSF C57BL/6 mice, 30 mg kg
-1
, daily 
for 14 days (CUS-exposed animals) 
Anti-stress CB1 receptor-mediated 
facilitation of hippocampal 
neurogenesis 
O’Brien et al., 
2013 
Light-dark test Sprague Dawley rats, 2.5 mg kg
-1
, 
i.p. for 14 days 
No effect Not tested 
Twardowschy 
et al., 2013 
Snake exposure Swiss mice, 3.0 mg kg
-1
, i.p. Panicolytic 5-HT1A receptor activation 
Almeida et 
al., 2013 
Social interaction test Wistar and SHR rats, 1 mg kg
-1
, i.p. Increased social interaction 
(Wistar rats only) 
Not tested 
Cheng et al., 
2014 
EPM C57BL/6J mice, 20 mg kg
-1
, i.p. 
daily for 21 days 
No effect Not tested 
Fogaça et al., 
2014 
EPM Wistar rats, 30 nmol, intra-PL 
cortex 
Anxiogenic (bell-shaped dose 
response curve), anxiolytic 24 hr 
after restraint stress 
5-HT1A receptor activation 
Nardo et al., 
2014 
MBT Swiss mice, 30 mg kg
-1
, i.p. Attenuated mCPP-induced 
increase in marble-burying (bell-
shaped dose response curve) 
Indirect CB1 receptor 
activation 
Marinho et 
al., 2015 
EPM Wistar rats, 15-30 nmol, intra-IL 
cortex 
Anxiolytic (bell-shaped dose 
response curve), no effect 24 hr 
after restraint stress 
5-HT1A receptor activation 
Todd and 
Arnold, 2016 
Open-field C57BL/6 mice, 10 mg kg
-1
, i.p. Prevented THC- induced 
anxiogenesis 
Not tested 
Schiavon et EPM Swiss mice, 3 mg kg
-1
, i.p. Anxiolytic Not tested 
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Table 2.  
Reference Test used Strain, species, effective dose and 
route/site of administration 
Effect Pharmacological 
mechanism 
Studies conducted in operant conditioning paradigms 
Silveira Filho 
and Tufik, 1981 
Geller-Seifter 
conflict test  
Wistar rats, 100 mg kg
-1
, i.p. No effect Not tested 
Musty et al., 
1985 
Vogel punished 
licking test  
Sprague-Dawley rats, 5-10 mg kg
-1
, 
i.p. 
Anxiolytic (bell-shaped dose-response 
curve) 
Not tested 
Moreira et al., 
2006 
Vogel punished 
licking test 
Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic Not blocked by BZD 
antagonism (flumazenil)  
Gomes et al., 
2011 
Vogel punished 
licking test 
Wistar rats, 30-60 nmol, intra-BNST Anxiolytic 5-HT1A receptor activation 
Studies conducted in classical (Pavlovian) conditioning paradigms 
Zuardi and 
Karniol, 1983 
AFC  Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Resstel et al., 
2006 
CFC Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Bitencourt et al., 
2008 
CFC Wistar rats, 6.4 nmol, i.c.v. Facilitated fear memory extinction Indirect CB1 receptor 
activation 
Lemos et al., 
2010  
CFC Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Lemos et al., 
2010 
CFC Wistar rats, 30 nmol, intra-PL cortex Anxiolytic (decreased fear expression) Not tested 
Lemos et al., 
2010 
CFC Wistar rats, 30 nmol, intra-IL cortex Anxiogenic (increased fear expression) Not tested 
ElBatsh et al., 
2012 
CFC Lister-hooded rats, 10 mg kg
-1
, i.p. 
daily for 14 days 
Anxiogenic (increased fear expression) Decreased hippocampal 
BDNF and TrkB, reduced 
frontal cortex phospho-
ERK1/2 expression 
Gomes et al., 
2012 
CFC Wistar rats, 30-60 nmol, intra-BNST Anxiolytic (decreased fear expression) 5-HT1A receptor activation 
Levin et al., CFC Wistar and SHR rats, 1-15 mg kg
-1
, Anxiolytic (decreased fear expression) Not tested 
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2012 i.p. and/or disrupted fear memory formation 
(Wistar rats only) 
Stern et al., 2012 CFC Wistar rats, 3-30 mg kg
-1
, i.p. Disrupted fear memory reconsolidation 
(bell-shaped dose response curve) 
Indirect CB1 receptor 
activation 
Do Monte et al., 
2013 
CFC Long–Evans hooded rats, 1.3 nmol, 
intra-IL cortex 
Facilitated fear memory extinction Indirect CB1 receptor 
activation 
Cheng et al., 
2014 
AFC C57BL/6J mice, 20 mg kg
-1
, i.p. daily 
for 21 days 
No effect Not tested 
Fogaca et al., 
2014 
CFC Wistar rats, 30 nmol, intra-PL cortex Anxiolytic (decreased fear expression) 5-HT1A receptor activation 
Gazarini et al., 
2014 
CFC Wistar rats, 10 mg kg
-1
, i.p. Disrupted fear memory reconsolidation Not tested 
Stern et al., 2014 CFC Wistar rats, 10 mg kg
-1
, i.p. Disrupted fear memory reconsolidation  Indirect CB1 receptor 
activation in PL cortex 
Marinho et al., 
2015 
CFC Wistar rats, 30 nmol, intra-IL cortex Anxiogenic (increased fear expression) 5-HT1A receptor activation 
Stern et al., 2015 CFC Wistar rats, 1 mg kg
-1
 + THC 0.1 mg 
kg
-1
, i.p. 
Disrupted fear memory reconsolidation Not tested 
Norris et al., 
2016 
OFC Sprague Dawley rats, 0.03-0.32 nmol, 
intra-nucleus accumbens shell 
Disrupted fear memory formation 
(acquisition) 
5-HT1A receptor activation 
Song et al., 2016 CFC Lister hooded rats, 10 mg kg
-1
, i.p., 
before extinction (after weak or strong 
conditioning) 
Impaired or enhanced extinction after 
weak or strong conditioning, 
respectively 
Not tested 
Jurkus et al., 
2016 
AFC Lister hooded rats, 5-20 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) 
at highest dose, no effect on extinction 
Not tested 
Stern et al., 2016 CFC Wistar rats, 10-30 mg kg
-1
, i.p. Disrupted fear memory consolidation Indirect CB1 or CB2 
receptor activation 
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Table 3.  
Reference  Subjects and test(s) used  Effective dose and route 
of administration 
Effect Possible pharmacological or neural 
mechanism 
Zuardi et al., 
1982 
Healthy subjects, THC-
induced anxiety 
~70 mg (1 mg kg
-1
) 
orally 
Prevented the anxiogenic 
effects of THC  
Not tested 
Zuardi et al., 
1993 
Healthy subjects, 
simulated public speaking-
induced anxiety 
300 mg orally Prevented public speaking-
induced increase in 
anxiety 
Not tested (effects similar to the 5-HT1A 
receptor partial agonist ipsapirone) 
Crippa et al., 
2004 
Healthy subjects, SPECT 400 mg orally Anxiolytic Decreased blood flow in medial temporal 
structures and posterior cingulate gyrus 
Fusar-Poli et 
al., 2009,  2010 
Healthy subjects, fearful 
faces, fMRI 
600 mg orally Anxiolytic (trend) Decreased blood flow in amygdala and 
anterior cingulate cortex that correlated 
with a reduced SCR to fearful faces 
Bergamaschi et 
al., 2011 
Social anxiety disorder 
patients, simulated public 
speaking-induced anxiety 
600 mg orally Anxiolytic Not tested 
Crippa et al., 
2011 
Generalized anxiety 
disorders patients, SPECT 
400 mg orally Decreased subjective 
anxiety 
Altered blood flow in limbic and 
paralimbic brain areas 
Hurd et al., 
2015 
Abstinent heroin abusers, 
heroin cue-induced anxiety 
400 or 800 mg orally Decreased subjective 
anxiety (preliminary data) 
Not tested 
Shannon and 
Opila-Lehman, 
2016 
A 10 year-old girl with 
PTSD (case report) 
At least 25 mg daily for 5 
months 
Reduced anxiety and 
improved sleep  
Not tested 
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